(Q37910891)

25 August 2017

1 reference

title

The challenges of gout management in the elderly (English)

1 reference

25 August 2017

1

Lisa K Stamp

1 reference

25 August 2017

Sarah Jordan

2

1 reference

25 August 2017

publication date

1 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

28

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

591-603

1 reference

Elderly-onset gout: a review

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Gender-dependent impacts of body mass index and moderate alcohol consumption on serum uric acid--an index of oxidant stress status?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Menopause, postmenopausal hormone use and serum uric acid levels in US women--the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Therapy insight: how changes in renal function with increasing age affect cardiovascular drug prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Comparison of indomethacin and phenylbutazone in acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Acid-related disorders in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Corticotropin for acute management of gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Does colchicine work? The results of the first controlled study in acute gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

21 January 2018

Colchicine update: 2008.

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Colchicine myopathy and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Quality of care indicators for gout management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

The role of interleukin-1 and the inflammasome in gout: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

A pilot study of IL-1 inhibition by anakinra in acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Association of uric acid with change in kidney function in healthy normotensive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Azathioprine and allopurinol: a potentially dangerous combination

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

The role of hyperuricemia in vascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Allopurinol and mortality in hyperuricaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Gout, allopurinol use, and heart failure outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Prevalence of contraindications and prescription of pharmacologic therapies for gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Long-term efficacy of hyperuricaemia treatment in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Fatal fulminant hepatic failure associated with benzbromarone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Fulminant hepatic failure associated with benzbromarone treatment: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Hepatic injury caused by benzbromarone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Gout therapeutics: new drugs for an old disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Post–cardiac transplantation gout: incidence of therapeutic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592750-000000000-00000

Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients

21 January 2018

1 reference

12 December 2020

Effects of Losartan on a Background of Hydrochlorothiazide in Patients With Hypertension

1 reference

12 December 2020

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study

1 reference

12 December 2020

British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout

1 reference

12 December 2020

Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level

1 reference

12 December 2020

Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia

1 reference

12 December 2020

Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions

1 reference

12 December 2020

Uricosuric effect of fenofibrate in healthy volunteers

1 reference

12 December 2020

Serum uric acid and renal prognosis in patients with IgA nephropathy

1 reference

12 December 2020

Hydrochlorothiazide versus spironolactone: long-term metabolic modifications in patients with essential hypertension

1 reference

12 December 2020

In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition

1 reference

12 December 2020

Learning how and when to employ uricase as bridge therapy in refractory gout.

1 reference

12 December 2020

New Haven survey of joint diseases. The prediction of serum uric acid in a general population

1 reference

12 December 2020

Treatment of Acute Gouty Arthritis with Proquazone and Indomethacin: A Comparative, Double-blind Trial

1 reference

12 December 2020

Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study

1 reference

12 December 2020

Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies

1 reference

12 December 2020

Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia

1 reference

12 December 2020

Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout

1 reference

12 December 2020

ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems

1 reference

12 December 2020

Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects

1 reference

12 December 2020

Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions

1 reference

12 December 2020

Effect of nonsteroidal anti-inflammatory drugs on the renal excretion of uric acid

1 reference

12 December 2020

Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis

1 reference

12 December 2020

Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation

1 reference

12 December 2020

Population serum urate levels and their correlates. The Sherbrooke regional study

1 reference

12 December 2020

Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study.

1 reference

12 December 2020

Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs

1 reference

12 December 2020

Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout

1 reference

12 December 2020

10.2165/11592750-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1033950488

0 references

1 reference